Introduction: Activated protein C is associated with a risk of bleeding and its effects on survival in septic shock patients are questionable. Protein C zymogen has no risk of bleeding and improves the outcome of patients with septic shock. We hereby describe the largest published case series of adult patients receiving protein C zymogen. Design, setting and participants: A prospective study on 23 adult patients with severe sepsis or septic shock, two or more organ failures and at high risk for bleeding, treated with protein C zymogen (50. IU/kg bolus followed by continuous infusion of 3. IU/kg/h for 72. h). Results: The Z-test evidenced a significant reduction between the expected mortality (53%) and the observed mortality 30% (Z value = 1.99, p= 0.046) in our sample population. Protein C levels increased from 34 ± 18% to 66 ± 22% at 6. h after PC bolus (p< 0.001), and kept on increasing during 72. h of administration (p< 0.001 to baseline). Sequential Organ Failure Assessment (SOFA), score of organ dysfunction, decreased from baseline to 7 days after administration of protein C from 14 ± 2 to 7 ± 4 (p< 0.001). No adverse event drug related was noted. Conclusion: Protein C zymogen administration is safe and its use in septic patients should be investigated through a randomized controlled trial. © 2012 Elsevier España, S.L. and SEMICYUC.
Protein C zymogen in adults with severe sepsis or septic shock
Bove T.;
2014-01-01
Abstract
Introduction: Activated protein C is associated with a risk of bleeding and its effects on survival in septic shock patients are questionable. Protein C zymogen has no risk of bleeding and improves the outcome of patients with septic shock. We hereby describe the largest published case series of adult patients receiving protein C zymogen. Design, setting and participants: A prospective study on 23 adult patients with severe sepsis or septic shock, two or more organ failures and at high risk for bleeding, treated with protein C zymogen (50. IU/kg bolus followed by continuous infusion of 3. IU/kg/h for 72. h). Results: The Z-test evidenced a significant reduction between the expected mortality (53%) and the observed mortality 30% (Z value = 1.99, p= 0.046) in our sample population. Protein C levels increased from 34 ± 18% to 66 ± 22% at 6. h after PC bolus (p< 0.001), and kept on increasing during 72. h of administration (p< 0.001 to baseline). Sequential Organ Failure Assessment (SOFA), score of organ dysfunction, decreased from baseline to 7 days after administration of protein C from 14 ± 2 to 7 ± 4 (p< 0.001). No adverse event drug related was noted. Conclusion: Protein C zymogen administration is safe and its use in septic patients should be investigated through a randomized controlled trial. © 2012 Elsevier España, S.L. and SEMICYUC.File | Dimensione | Formato | |
---|---|---|---|
Protein C zymogen in adults with severe sepsis or septic shock.pdf
non disponibili
Tipologia:
Versione Editoriale (PDF)
Licenza:
Non pubblico
Dimensione
362.68 kB
Formato
Adobe PDF
|
362.68 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.